generics
Pay-for-delay deals up 60% in US
May 6, 2011Sales and Marketing FTC, generics
Deals to delay generic drugs from coming onto the US market have more than doubled. The Federal Trade Commission’s staff …
Cephalon accepts Teva’s $6.8 billion white knight bid
May 3, 2011Research and Development, Sales and Marketing Cephalon, Teva, Valeant, generics
Generics giant Teva has acquired Cephalon for $6.8 billion and says the deal will make it a leading specialty pharmaceutical …
Indian firm Dr Reddy’s opens UK site
April 12, 2011Sales and Marketing Cambridge, Chirotech, Dr Reddy's, India, generics
Indian firm Dr Reddy’s has confirmed the UK is still attractive for investment as it opens its new pharma services …
Eisai to cut 900 jobs ahead of Aricept patent loss
March 7, 2011Sales and Marketing Aricept, Eisai, donepezil, generics, job cuts
Eisai is to cut around 900 jobs in Europe, the US and Japan over the next five years as it …
Obama’s generics plan criticised
February 15, 2011Sales and Marketing FDA, Obama, PhRMA, generics, reform
US pharma says new plans to end ‘pay-for-delay’ generics deals and shave five years from biologics exclusivity will threaten innovation …
Generics force Sanofi into standstill
February 9, 2011Sales and Marketing 2010 pharma results, Jevtana, Multaq, Sanofi, Sanofi-Aventis, generics
An onslaught of generic competition combined with healthcare cuts in the US and Europe meant Sanofi-Aventis’ revenues were brought to …
Teva plant in Israel cited by FDA, expands in Americas
February 8, 2011Manufacturing and Production Corporacion Infarmasa, FDA, Peru, Teva, Teva Pharmaceutical, generics, generics manufacturing, manufacturing compliance
A manufacturing facility in Jerusalem operated by Teva Pharmaceutical failed to pass muster in an FDA inspection, prompting a warning …
European Commission launches new generic deal review
January 18, 2011Sales and Marketing European Commission, anti-trust investigation, competition, generics
The European Commission has asked a number of firms to submit copies of their patent settlements in 2010 to see …
Pfizer pays $63m for generics portfolio
January 5, 2011Sales and Marketing Akorn, Akorn-Strides, Pfizer, Strides Arcolab, generics, injectables
Pfizer has bolstered its generics portfolio, paying around $63 million for 22 drugs. The company will buy 16 Abbreviated New …
Two thirds of pharma companies face ‘strategic crisis’
October 25, 2010Research and Development, Sales and Marketing Novartis, Pfizer, Roland Berger, generics, pharma research, pharma sales
The pharma industry is moving away from traditional in-house innovation and toward a more diversified business model, but will encounter …
Government drops generic substitution plans
October 15, 2010Sales and Marketing NHS, generics, government
The coalition government has dropped plans to implement generic substitution in England. The Pharmaceutical Price Regulation Scheme (PPRS), a scheme …
Generic Lovenox to dent Sanofi’s earnings
July 26, 2010Sales and Marketing Lovenox, Sandoz, Sanofi-Aventis, generics
A generic version of Sanofi-Aventis’ blockbuster anti-blood clot treatment Lovenox has just gained approval in the US, signaling a rapid …
European Court upholds AZ Losec judgement
July 2, 2010Sales and Marketing AstraZeneca, Losec, generics
The General Court of the EU has upheld the European Commission’s 2005 decision that AstraZeneca were guilty of blocking cheaper …
Third Apotex plant cited in FDA warning letter
April 19, 2010Manufacturing and Production Apotex, generics, manufacturing compliance
Canada’s Apotex has been sent a warning letter citing manufacturing violations at a facility in Toronto that are identical to …
Novartis set to boost generic portfolio
April 19, 2010Sales and Marketing Novartis, Sandoz, generics
Novartis’ generics arm Sandoz has signed a deal to acquire US-based inhalable drug specialist Oriel Therapeutics. Sandoz will gain rights …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
